Rituximab leads to early elimination of circulating CD20+ T and B lymphocytes in patients with iTTP despite ongoing TPEx

•How TPEx impacts rituximab effectiveness in iTTP patients is not fully understood.•In iTTP patients on therapeutic plasma exchange, rituximab eliminates circulating CD20+ B and T cells in 24 hours for at least 1 week.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood advances 2020-02, Vol.4 (3), p.477-481
Hauptverfasser:	Carden, Marcus A., Gaddh, Manila, Hoskote, Abhinav, Brown, Michael, Merrill, Virginia, Stowell, Sean R., Chandrakasan, Shanmuganathan, Antun, Ana, Kudchadkar, Ragini, Kotanchiyev, Sarah, Jaye, David L., Bodó, Imre
Format:	Artikel
Sprache:	eng
Schlagworte:	Antigens, CD20 B-Lymphocytes Exceptional Case Report Hematology Humans Life Sciences & Biomedicine Longitudinal Studies Rituximab Science & Technology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	•How TPEx impacts rituximab effectiveness in iTTP patients is not fully understood.•In iTTP patients on therapeutic plasma exchange, rituximab eliminates circulating CD20+ B and T cells in 24 hours for at least 1 week.
ISSN:	2473-9529 2473-9537
DOI:	10.1182/bloodadvances.2019001148